Results 131 to 140 of about 119,295 (311)

Prognostic and Predictive Value of Lymph Node Ratio in Stage III Colon Cancer in the Era of Molecular Biomarkers

Journal of the Anus, Rectum and Colon
Background: The prognostic and predictive value of the lymph node ratio (LNR; metastatic/harvested nodes) in stage III colon cancer (CC) remains unclear, particularly in combination with molecular profiles such as RAS, BRAF, and microsatellite ...
Zhenxin Rao, Kozo Kataoka, Ayako Imada, Kazuma Ito, Yuko Fukumoto, Kei Kimura, Jihyung Song, Yuki Horio, Ryuichi Kuwahara, Motoi Uchino, Wim Ceelen, Masataka Ikeda   +11 more
doaj   +1 more source

Understanding BRAF mutation in NSCLC patients

reservedINTRODUZIONE BRAF è un gene la cui mutazione si ritrova in molti tumori tra cui quelli polmonari non a piccole cellule (NSCLC) e che, nonostante la sua fre-quenza sia rara, rappresenta un target per la terapia oncologica mirata.
SQUARZONI, GIULIA
core  

Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF

, 2019
BRAF is the most frequently mutated kinase in human cancers and is one of the major effectors of oncogenic RAS, making BRAF a target of considerable interest for anticancer drug development.
Amber Y. Gunderwala, Zhihong Wang, Zhihong Wang (142713), Anushri A. Nimbvikar, Nicholas J. Cope, Amber Y. Gunderwala (6847520), Anushri A. Nimbvikar (6847523), Zhijun Li, Zhijun Li (475291), Nicholas J. Cope (6847526)   +9 more
core   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma

International Journal of Cancer, EarlyView.
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem, Melissa M. de Meza, Cato D. M. Boreel, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers‐Sonderen, Han J. Bonenkamp, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Bart Rikhof, Lieke H. J. Simkens, Marion A. Stevense‐den Boer, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Alfonsus J. M. van den Eertwegh, Michel W. J. M. Wouters   +20 more
wiley   +1 more source

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation

, 2015
Florin Zaharie,1,* Roxana Cojocneanu-Petric,1,* Mihai Muresan,1 Ioana Frinc,2 Delia Dima,2 Bobe Petrushev,3 Alina Tanase,4 Cristian Berce,1 Mariana Chitic,2 Ioana Berindan-Neagoe,1 Valentina Pileczki,1 Alexandru Irimie,5 Ciprian Tomuleasa2 1Iuliu ...
Chitic M, Tomuleasa C, Cojocneanu-Petric R, Berindan-Neagoe I, Frinc I, Pileczki V, Irimie A, Zaharie F, Muresan M, Petrushev B, Tanase A, Dima D, Berce C   +12 more
core  

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

BRAF [PDF]

Science-Business eXchange, 2013
openaire   +3 more sources

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

A BRAF-Negative Classic Hairy Cell Leukemia Patient with LongLasting Complete Remission after Rituximab and Pentostatin

Turkish Journal of Hematology, 2020
Alessandro Gozzetti, Vincenzo Sammartano, Francesca Bacchiarri, Donatella Raspadori, Monica Bocchia   +4 more
doaj   +1 more source